

isogenica

Nature Communications publishes UMC Utrecht and Isogenica research on VHH-mediated targeting of LRP5 and LRP6

Under a collaboration between Isogenica and scientists at the Oncode Institute and University Medical Center Utrecht, led by Professor Madelon Maurice, Isogenica's fully synthetic, highly diverse LlamdA™ library was screened for Wnt pathway inhibitors using CIS Display, the company's *in vitro* library selection system. This promising new strategy for treatment of Wnt-hypersensitive tumours using VHH-mediated targeting of LRP5 and LRP6 has been published in Nature Communications.



Article | [OPEN](#) | Published: 21 January 2019

Anti-LRP5/6 VHHs promote differentiation of Wnt-hypersensitive intestinal stem cells

Nicola Fenderico, Revina C. van Scherpenzeel, Michael Goldflam, Davide Proverbio, Ingrid Jordens, Tomica Kralj, Sarah Stryeck, Tarek Z. Bass, Guy Hermans, Christopher Ullman, Teodor Aastrup, Piet Gros & Madelon M. Maurice 

"LlamdA™ library derived VHH antibodies block both LRP5 and LRP6 driven Wnt signalling in stem cells without activating the receptors that bivalent conventional antibodies do. This re-opens the perspective for development of VHH-driven biotherapeutics for Wnt/b-catenin sensitive tumours. Our collaborative effort exemplifies both the added value of the VHH format over conventional monoclonal antibodies, as well as the benefit of using a synthetic VHH library such as LlamdA™ to discover antibody fragments to challenging targets and epitopes". - Dr. Guy Hermans, CSO

[Read the press release](#)



Meet Isogenica at Bio-Europe and CEO Emma Sceats at the Europe CEO meeting, taking place on 24th March. This will be an exciting opportunity to network with potential partners. Email bd@isogenica.com to connect.

Isogenica has expanded its collaboration with Aro Biotherapeutics. Under the expanded agreement, Isogenica will use its CIS Display platform to help Aro achieve its goal of developing novel Centyrins™ against multiple targets for cell - specific delivery.



Speed and success through our focus on synthetic antibodies.
Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on our proprietary fully synthetic antibody libraries and leveraging our CIS Display and Colibra™ technologies to accelerate discovery.



Copyright © 2019 Isogenica, All rights reserved.

Your data is important to us. View our privacy policy [here](#)

Our mailing address is:
info@isogenica.com

Want to change how you receive these emails?
You can [unsubscribe from this list](#).

This email was sent to ***[EMAIL]***
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
[LIST:ADDRESSLINE]